16th European AIDS Conference (EACS) 25-27 October 2017

Oral Presentations:
The hepatitis C cascade of care among HIV infected individuals in EuroSIDA​ presented by Sarah Amele. PRESENTATION
27 October 2017: 10:15 AM in Room Barcelona. PS9/1

Use of PEP and PrEP among HIV Negative MSM in the PARTNER Study presented by Valentina Cambiano. PRESENTATION
27 October 2017: 11:15-11:30 in Room Belgrade. PS11/4

Poster Presentations: (26 & 27 October 2017 12:00-14:00 in the Exhibition Hall)
Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort presented by Ashley Roen. POSTER
PE9/25
 
Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase inhibitors: Results from the EuroSIDA study  presented by Leah Shepherd. POSTER
PE12/7

Collaboration with COHERE: "Estimating the country-specific burden of late presentation to HIV care across Europe between 2010-2014 presented by Kamilla Laut on behalf of the Late Presentation Working Group in the COHERE and EuroSIDA studies. POSTER
PE26/6

OptTEST programme interventions for Indicator Condition HIV testing significantly increase HIV testing rates​ presented by Ann Sullivan. POSTER
PE23/15

Barriers in offering HIV testing in medical settings are likely to be addressed with short and targeted education - data from expanded staff questionnaire OptTEST project presented by Justyna Kowalska. POSTER
PE25/21


ID WEEK 2017, San Diego California 4-8 October 2017

Oral Presentations:
Induced Hypothermia in Patients with Septic Shock and Ventilaor-demanding Respiratory Failure presented by Jens-Ulrik Stæhr Jensen. PRESENTATION
6 October 2017:10:45 AM. Oral Abstract Session: Advances in Management of Bacteremia and Sepsis, Room: 07AB

Poster Presentations:
Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results presented by Neval Ete Wareham. POSTER
7th October 2017. Poster Abstract Session: Transplant Infections - Epidemiology, Poster Hall CD

Impact of CMV PCR Blips in Recipients of Solid Organ and Haematopoietic Stem Cell Transplantation presented by Isabelle Lodding. POSTER
7th October.Poster Abstract Session: Viral Infections in Transplantation. Room: Poster Hall CD

Lymphopenia after Radiotherapy and Risk of Infection presented by Cynthia Terrones. POSTER
7th October 2017. Poster Abstract Session: Transplant Infections - Epidemiology, Poster Hall CD

Clostridium difficile Infection in Solid Organ and Haematopoietic Stem Cell Transplant Recipients presented by Emma Elizabeth Ilett. POSTER
7th October. Poster Abstract Session: Transplantation - Bacterial Infections. Room: Poster Hall CD

Renal Dysfunction in a Cohort of Renal Transplant Recipients: Impact of BK Polyomavirus presented by Álvaro H. Borges. POSTER
7th October. Poster Abstract Session: Viral Infections in Transplantation. Room: Poster Hall CD

Prediction of Febrile Neutropenia after Chemotherapy Based on Pre-treatment Risk Factors among Cancer Patients presented by Theis Aagaard. POSTER
7th October.Poster Abstract Session: Transplant Infections - Epidemiology. Room: Poster Hall CD

Febrile neutropenia as a marker of an infectious phenotype and poor long-term outcomes among patients treated with chemotherapy for malignant diseases presented by Josephine Nordvig. POSTER
7th October.Poster Abstract Session: Transplant Infections - Epidemiology. Room: Poster Hall CD​

The 9th IAS Conference on HIV Science, Paris France 23-26 July 2017

Oral Presentation:

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries presented by Nanina Anderegg on behalf of the LeDEA & COHERE collaborations
24th July AT 11 am, Session: MOAB0101

Poster Presentations:

Universal access? Legal and regulatory barriers to accessing HIV treatment across Europe that damage public health and hinder treatment as prevention presented by Lisa Power on behalf of OptTEST

Participant reasons for not initiating antiretroviral treatment despite compelling evidence following early unblinding of the Strategic Timing of Antiretroviral Treatment (START) trial presented by Giulio Maria Corbelli on behalf of the INSIGHT START Study Group

Association of sub-optimal antiretroviral therapy (ART) adherence with inflammation in virologically-suppressed, HIV-infected individuals: a sub-analysis of the strategies for management of antiretroviral therapy (SMART) study
presented by Edward M. Gardner on behalf of the INSIGHT SMART Study Group

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: results from the D:A:D study presented by Mark Alastair Boyd on behalf of the D:A:D Study Group. POSTER


Are health systems addressing comorbidities in people living with HIV? An assessment of key European HIV guidelines and monitoring mechanisms presented by Jane Anderson. POSTER. Abstract

The International Liver Congress 2017, Amsterdam The Netherlands 19-23 April 2017

Oral Presentation:
Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study presented by Jeffrey V. Lazarus. PRESENTATION. Abstract

Poster Presentation:
Implementing the WHO Global Health Sector Strategy on Viral Hepatitis in Denmark – modeling the effects of community-based care on the elimination of HCV by 2030 presented by O Henriksen. POSTER. Abstract

Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe presented by AD Marshal. POSTER. Abstract

Joint workshop 19th April 10-11:
Direct-acting antiviral availability and reimbursement restrictions in Europe: Policy implications for treatment of people who inject drugs presented by Jeffrey Lazarus

ELPA Symposium 20th April:
What is ELPA doing for the liver? Hep-CORE survey presented by Jeffrey V. Lazarus 

The 24th Conference on Retroviruses and Opportunistic Infections, Seattle Washington, 13th - 16th February 2017

Oral Presentations:
Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors. presented by Lene Ryom on behalf of the D:A:D. Presentation:  O-12/128, Thursday 16th February 10.30-10-45. PRESENTATION. WEBCAST

Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study. presented by Leah Shepherd on behalf of D:A:D 
Presentation: O-12/131, Thursday 16th February 11.15 - 11.30. PRESENTATION . WEBCAST

Darunavir/r use and incident chronic kidney disease in HIV-positive persons. Presented Lene Ryom on behalf of D:A:D. 
Poster: P-02/653,Tuesday 14th February 14.30-16.00 (Session on ART and toxicity) POSTER

Benefit of continous/immediate ART on disease risk: SMART and START combined analysis. Presented by Alvaro Borges on behalf of SMART and START.
Poster: P-G5/474, Thursday 16th February 14.30-16.00. POSTER

Effectiveness and cost-effectiveness of screening strategies across Europe. Presented by Yazdan Yazdanpanah on behalf of OptTEST.
Poster:  P-X2/1028, Tuesday 14th February 14.30-16.00. POSTER

HepHIV 2017 Conference, Malta 31 January - 2 February 2017

Oral presentations:
10 years of HIV in Europe – what has been achieved, what remains as challenges. presented by Jens Lundgren and Ton Coenen. 

Monitoring HIV-indicator condition based HIV testing in Estonia, presented by Liis Lemsalu on behalf of OptTEST. (Oral and Poster). PRESENTATION  POSTER

Barring the Way to Health: how legal and regulatory barriers hinder modernising HIV testing across Europe, presented by Lisa Power on behalf of OptTEST. (Oral and Poster). PRESENTATION  POSTER

Organizational barriers as an explanation for differences in offer and uptake rates for hepatitis B/C and HIV testing in three drug addiction centres in Copenhagen presented by Marianne Linnet on behalf of SACC (Oral and Poster). PRESENTATION  POSTER

Poster presentations:
Variation in ART-coverage and virological suppression among HIV key populations, presented by Kamilla Laut on behalf of EuroSIDA. PO1/14. POSTER

HIV testing improvement in primary care through Opt-TEST´s indicator condition guided testing: The Tool-1 and Plan-Do-Study-Act experience in Catalonia, 2016, presented by Rossie Lugo on behalf of OptTEST. PO3/05. POSTER

Availability of HIV testing in health care, community-based and home-based settings in the EU/EEA Member States, presented by Ekaterina Filatova on behalf of HIV in Europe. PO1/13. POSTER

Missed opportunities for diagnosing viral hepatitis testing in Europe: a 25-country analysis presented by Jeff Lazarus on behalf of Hep-CORE Study Group. PO2/01. POSTER